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Summary The purpose of our study was to investigate the efficacy and toxicity of paclitaxel in patients with
relapsed or refractory epithelial ovarian cancer in the context of a large multicentre study performed in the
UK and Eire. Patients with previously treated epithelial carcinoma of the ovary or fallopian tube who fulfilled
the eligibility criteria were entered in the study. Eligibility criteria included: measurable or evaluable disease;
Eastern Cooperative Oncology Group (ECOG) performance status 0-2; up to three prior chemotherapy
regimens, one of which had to contain a platinum agent; adequate haematological, renal and hepatic function;
and no significant cardiac history. Patients received either 175 mg m-2 or 135 mg mj2,paclitaxel. The lower
dose was administered to patients who had received more than two prior chemotherapy regimens. Paclitaxel
was given by i.v. infusion over 3 h every 21 days. Response was assessed at three-cycle intervals or earlier if
required. A total of 155 patients were registered for the study in the UK of whom 140 were eligible for
response and toxicity evaluation, and 12 patients were assessed for toxicity only. Hair loss was the most
frequently reported toxicity, with 74% (119/152) of patients reporting grade 3 alopecia. The most frequently
reported serious toxicity was neutropenia, with 49% (74/152) of patients experiencing neutropenia grade 3 or
4. The response rate was 16% [two complete responders (CR), 20 partial responders (PR)], the median
duration of response was 275 days and median survival was 244 days. Paclitaxel is active in relapsed and
platinum-resistant epithelial ovarian cancer. It is well tolerated and can be given in an out-patient setting. The
UK and Eire experience is very similar to that of US investigators in this group of patients. Further work is
required to assess the optimal use of the drug in both first- and second-line therapy.
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Ovarian cancer is the fifth commonest cause of cancer death
in European women. The majority of patients present with
advanced disease for which the treatment is surgery followed
by chemotherapy. Platinum-containing chemotherapy
regimens have become the standard first-line treatment in
advanced disease but although the majority of patients
experience an objective clinical response less than 20% of
patients experience long term disease-free survival (Cannistra,
1993). At relapse, second-line treatment with platinum-based
regimens can produce useful palliation. In these circums-
tances the response rate is dependent on the duration of
response to first-line platinum (Gore et al., 1990; Markman
et al., 1991). In the majority of patients tumours eventually
become refractory to platinum treatment and response to
other conventional agents is unusual.
Paclitaxel is an antimitotic agent derived from the bark of
Taxus brevifolia (pacific yew tree) which acts by stabilising
and promoting microtubule assembly (Schiff et al., 1979).
Responses to paclitaxel in ovarian cancer were shown in 1989
when McGuire et al. (1989) reported a 25% response rate in
patients with persistent or refractory epithelial ovarian
cancer. Other reports of activity followed and the overall
response rate for 189 patients in five studies was 29%
(19-40%), with durable responses of more than 1 year in
some patients. Many of these patients had tumours resistant
to platinum-based chemotherapy (Einzig et al., 1989, 1992;
Thigpen et al., 1990; Sarosy et al., 1992).
Owing to the widespread perception of possible benefit
that paclitaxel may provide, a protocol was designed for
compassionate treatment of patients with refractory or recur-
rent disease following platinum and other therapies. The
entry criteria were deliberately permissive with regard to
previous treatment in an attempt to reflect more accurately
commonly encountered clinical situations.
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Patients and methods
The study was initiated in the UK and Eire in August 1992
and 11 centres participated. Patients aged between 18 and 75
with histologically proven epithelial carcinoma of the ovary
or fallopian tube with measurable disease were eligible.
Eligibility criteria included: (1) prior treatment with at least
one platinum containing regimen but a maximum of three
previous chemotherapy regimens; (2) Eastern Cooperative
Oncology Group (ECOG) performance status 0-2; (3)
absolute neutrophil count (ANC) >2.0 x I091-1, platelet
count > 100 x I091'; (4) adequate renal and hepatic func-
tion (creatinine <1.5 times upper normal limit, total bili-
rubin <1.25 times upper normal limit); (5) no significant
cardiac history (myocardial infarction within the past 6
months; second- or third-degree heart block, congestive heart
failure or atrial/ventricular arrhythmias).
The dose of paclitaxel was determined by the number of
prior chemotherapy regimens. Patients previously treated
with one or two regimens received 175 mgm2 and patients
treated with three prior regimens received 135 mgm2. Pac-
litaxel was administered over 3 h by continuous i.v. infusion
every 21 days. All patients were pretreated with 40 mg of oral
dexamethasone, given as 20 mg 12 and 6 h before paclitaxel
and 300 mg of cimetidine and 10 mg of chlorpheniramine i.v.
30 min before each treatment. Paclitaxel treatment was con-
tinued for a maximum of ten cycles, until disease progression
or four treatment cycles after a complete response had been
obtained.
Toxicities were graded according to WHO criteria. Dose
reductions were required for haematological and non-
haematological toxicities. ANC or platelet counts falling to
<0.5 x I09 1-' or <50 x I09 1-' respectively over a period of
7 days or more required doses to be reduced two levels. ANC
or platelet counts over 7 days or more of 0.5- 0.99 x 109 1-1
and 50-99 x 109 1' respectively required reductions of one
dose level. Patients experiencing mucositis with vesiculation
and/or ulcers had their dose reduced by one dose level. Dose
levels were defined as 175, 135, 100 and 90mgm2. Patients
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90mgm2. Patients were removed from the study for any
major organ toxicities of WHO grade 2 or more or requiring
dose reductions below 90 mg m-2. For patients experiencing
any significant hypersensitivity reaction (hypotension requir-
ing pressor therapy, angioedema, respiratory distress requir-
ing bronchodilation therapy, generalised urticaria) the
infusion was stopped. At the investigator's discretion the
infusion was continued with the remainder of the dose being
given over a 24 h period with an increased dose of dex-
amethasone premedication (8 mg given at 24, 18, 12 and 6 h
before treatment). The patient was removed from the study if
any further significant hypersensitivity reaction occurred.
At study entry, patients were assessed clinically and ECG,
chest radiographs, laboratory studies and tumour
measurements were performed. During the study
haematological parameters were measured weekly and
biochemical parameters and toxicities assessed every 21 days.
Tumour measurements were reassessed after every three
cycles of treatment by CT scan or ultrasound in the majority
of cases. A complete response (CR) was defined as the com-
plete disappearance of all evidence of tumour determined by
two observations not less than 4 weeks apart. Partial res-
ponse (PR) was defined as a decrease of at least 50% in the
sum of the products of measured lesions without the
appearance of new lesions for a minimum of 4 weeks.
Patients with stable disease had changes in measurable
disease which were too small to be classed as partial or
progressive disease and no appearance of new lesions over a
4 week period. Development of any new site of disease or an
increase of more than 25% in the product of the measured
lesions constituted progressive disease. Serum CA125 and
clinical criteria were not used to determine response. Dura-
tion of response was defined from the date of when PR or
CR criteria were first met until clinical or radiological pro-
gression.
Results
Between August 1992 and April 1993, 155 patients in the UK
and Eire were registered for the study (three did not receive
any treatment and are not included in the analysis). The
remaining 152 patients were treated with either 175 mgm2
(124 patients) or 135 mgm2 (28 patients). Twelve patients
(five patients, 135 mgm2; seven patients, 175 mgm2) did
not satisfy eligibility criteria but were treated on compas-
sionate grounds; they are not included in the evaluation of
response but are included in the toxicity assessment. Three
patients had fallopian tube carcinoma. The median age of all
the patients was 55 years (range 21-76) with a median
performance status of 1 (range 0-2). Eighty-five per cent
(131/155) of the patients enrolled had multiple lesions and
55% (85/155) had a measurable lesion of greater than 5 cm.
Sixty-one per cent (95/155) of patients had received two or
three previous chemotherapy regimens with a median
chemotherapy-free interval of 92.5 days (range 0-1186).
Twenty-five per cent (39/155) had tumours refractory to
platinum treatment (defined as progression through last
platinum-containing chemotherapy). The median number of
paclitaxel courses administered per patient was six. Dose
reductions were required in 12% (19/152) of all treated
patients, 47% (9/19) of the reductions were required for
non-haematological toxicities. The median follow-up time
was 215 days (range 13-582). The two treatment groups (175
and 135 mg m-2) were similar in terms of demographics,
disease extent, response (to previous treatment) and tox-
icity.
Toxicity
Toxicity in the 152 treated patients is shown in Figure 1.
Grade 3 or 4 neutropenia was reported in 49% (74/152) of
patients with two patients requiring admission to hospital for
septicaemia. Generally, however, the duration of neutropenia
was short and without serious complications. Only four
patients (5%) required a reduction in dosage and one patient
had treatment delayed 7 days. Grade 3 or 4 throm-
bocytopenia was uncommon, being reported in 4% (6/152) of
patients.
No significant hypersensitivity reactions (as defined in
Patients and methods) were reported. Minor reactions were
reported in 62% (94/152) of patients with facial flushing, the
most commonly occurring event. Treatment interruption due
to hypersensitivity reactions was rare, reported on only five
occasions. In all but one patient the paclitaxel infusions were
continued and full doses received.
Grade I or II sensory neuropathy was experienced by 52%
(79/152) of patients. This was generally apparent after the
first two cycles of Taxol, but in most cases was not of
sufficient severity to compromise further treatment. Grade III
or IV neuropathy occurred in 9% (14/152) of patients with
motor loss experienced by only one patient.
The majority of patients developed grade 3 alopecia (119/
152), no grade 4 alopecia was recorded. Nausea and vomiting
was noted in 68% (103/152) of patients but was generally not
severe with only 17% (26/152) classified as grade 3-4. Grade
3 myalgia/arthralgia occurred in 9% (14/152) of patients.
There were no deaths due to toxicity although 6% (9/152)
patients required dose reduction due to non-haematological
toxicity: peripheral neuropathy (seven patients); polyar-
thropathy (one patient); decreased performance status (one
patient). Fifteen patients (10%) were withdrawn from the
study due to drug-related toxicities which were
predominantly peripheral neuropathy (seven patients) or
myalgia/arthralgia (three patients).
Response
The response rate in the 140 patients eligible for response
evaluation was 16% (2 CR, 20 PR). Forty-five patients
(32%) had stable disease while 62 patients (48%) progressed
on treatment. All responses were independently verified.
None of the patients with fallopian tube carcinoma res-
ponded to treatment. Of those patients whose disease pro-
gressed through their last chemotherapy (platinum or non-
platinum) 17% responded to paclitaxel, the same response
rate was obtained for those patients with tumours refractory
to platinum treatment. The median duration of response was
275 days (95% CI > 200 days) and median survival time was
244 days (95% CI 191-299 days). A plot of the survival
curve is shown in Figure 2.
Discussion
Relapsed or platinum-refractory epithelial ovarian cancer is
incurable. Phase II studies show that response rates in this
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Figure 2 Survival curve.
Table I Response to paclitaxel analysed by the number of prior
platinum regimens and the time between last chemotherapy and
commencing paclitaxel (treatment-free interval)
Response rate (%)
One prior platinum regimen (14/86) (16)
Two or three prior platinum regimens (8/54) (15)
Treatment-free interval <6 months (15/97) (15)
Treatment-free interval >6 months (7/41) (17)
Data on treatment-free interval was not available in two patients
(responders/total number of patients)
situation are low and depend on the interval between the end
of the previous treatment and start of the phase II study
(Blackledge et al., 1989). Patients who progress on primary
treatment or relapse within 6 months of primary treatment
have a particularly poor prognosis and most of the patient
population studied here fall into this category. Eighty-five per
cent of our patients had multiple sites of disease, often bulky
and their median time since last chemotherapy was short at
92.5 days with 97 patients (63%) having a treatment-free
interval of less than 6 months. A response rate of 16% in this
group therefore compares favourably with response rates of
10% or less seen with other phase II agents (Blackledge et
al., 1989). It is also of interest that the response rate did not
vary with treatment-free interval, or the number of previous
platinum regimens (Table I). Ninety-five patients (61%) had
been treated with two or three chemotherapy regimens and in
fifty-four patients these had all been platinum containing. A
response rate of 15% in this group is encouraging as is the
response rate of 17% in patients with tumours refractory to
platinum. The duration of response in patients with recurrent
ovarian cancer who respond to salvage therapy is in the
order of 4-7 months (Thigpen et al., 1993). The median
duration of response (275 days or 9 months with a 1 year
survival rate of 35%) again compares favourably. The results
from this study are consistent with those of Trimble et al.
(1993) who showed that in a group of heavily pretreated
patients (having undergone three or more prior
chemotherapy regimens) with recurrent tumour within 3
months, treatment with paclitaxel resulted in a 21% response
rate.
Toxicity is a major issue in the development of new
therapies for relapsed or platinum-resistant ovarian cancer
since treatment is essentially palliative. In this report there
were no treatment-related deaths and although WHO grade 3
and 4 toxicities were encountered they only rarely resulted in
serious complications for the patient. Almost half of the
patients experienced grade 3 or 4 neutropenia but only 4%
had grade 3 or 4 thrombocytopenia. The duration of neut-
ropenia was very short with recovery nearly always complete
at day 21 and only six patients (4%) required a dose reduc-
tion. Patients receiving more than three prior chemotherapy
regimens were given the lower dose of paclitaxel in order to
minimalise possible haematological toxicities. However, the
median neutrophil nadir for this group, 1.46 x IO 1'- (range
0.1-4.7) compared with 0.9 x 109 1- (range 0.0-8.5) in the
175 mg m-2 group suggests that these patients could tolerate
the higher dose. Hypersensitivity reactions were well cont-
rolled by premedication and only five patients had treatment
delayed because of this complication. Less than 20% of
patients had grades 3 or 4 nausea/vomiting or peripheral
neuropathy and only 10% of patients withdrew from the
study because of toxicity. The major toxicity in this study
was alopecia, and this is a serious side-effect for any pal-
liative treatment. However, when given as a 3 h infusion
paclitaxel can be administered in the out-patient setting, and
it was the experience of all investigators that patients
tolerated treatment well. The duration of responses was short
but no shorter than with other therapies and it remains to be
seen whether or not paclitaxel improves survival and quality
of life in this patient group. The activity of paclitaxel in a
group of patients with a poor prognosis such as those studied
here suggests that paclitaxel has a place as first-line
chemotherapy in advanced epithelial ovarian cancer. One of
the first studies to investigate this question (GOG11) com-
pared cisplatin and paclitaxel (75 mgm2 and 135 mgm12)
with cisplatin and cyclophosphamide (75 mg m-2 and
750 mg m-2) in patients with suboptimally debulked stage III
and IV ovarian cancer. Initial results from 209 evaluable
patients showed a greater response rate in the cisplatin/
paclitaxel arm (79% vs 63% P<0.01; McGuire et al., 1993).
Median survival was also significantly improved in the
cisplatin/paclitaxel arm (37.5 months vs 24.4 months
cisplatin/cyclophosphamide P=0.0001:relative risk 0.59 for
cisplatin/paclitaxel; McGuire et al., 1995). The cisplatin/
paclitaxel regimen showed greater toxicity in terms of neut-
ropenia, fever, peripheral neurotoxicity and alopecia. How-
ever, this increase in toxicity was not reflected in discontinua-
tions for adverse events (7% cisplatin/paclitaxel vs 6%
cisplatin/cyclophosphamide) or the ability to administer
treatment on schedule with the overall dose of cisplatin being
equal in both arms. These are encouraging results and fur-
ther studies to assess activity both as single agent and in
combination are currently under way.
Paclitaxel is active in relapsed and platinum-resistant
epithelial ovarian cancer, is well tolerated and can be given in
the out-patient setting. It is a valuable addition to the treat-
ment options available and can produce useful palliation
with limited controllable toxicity. However, the prognosis for
this group of patients as a whole remain poor.
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